产科医生和AI医疗研究者值得关注——这项研究用常规产检数据解决了P-TMA早期预测难题，梯度提升模型表现可靠，且胱抑素C指标易于临床落地。建议点开看看具体特征分析和模型细节。
妊娠相关血栓性微血管病（P-TMA）罕见但致命，早期风险预测极具挑战，因为其实验室异常常被妊娠期生理变化掩盖。该研究纳入300例妊娠（142例P-TMA，158例对照），利用146个纵向实验室指标，评估了五种机器学习算法。梯度提升模型在测试集上达到AUROC 0.872、AUPRC 0.883，敏感度0.750，特异度0.812。研究发现，第6周的胱抑素C可作为早期监测指标。这项工作展示了常规产检数据经机器学习分析后，能有效识别P-TMA风险信号。
Interpretable Machine Learning for Antepartum Prediction of Pregnancy-Associated Thrombotic Microangiopathy Using Routine Longitudinal Laboratory Data
Background: Pregnancy-associated thrombotic microangiopathy (P-TMA) is rare but life-threatening. Early risk prediction before overt clinical presentation remains challenging, as the associated laboratory abnormalities are subtle, multidimensional, and frequently masked by common physiological changes such as gestational thrombocytopenia and pregnancy-related proteinuria, thus overlapping heavily with benign obstetric and renal conditions. This complexity is poorly captured by univariate or rule-based approaches; however, it is addressable by machine learning, which can extract latent, time-dependent risk signatures from longitudinal clinical tests. Methods: This retrospective study included 300 pregnancies comprising 142 P-TMA cases and 158 controls. After exclusion of identifiers and non-informative variables, 146 longitudinal laboratory predictors were retained. Participants were divided into a training cohort (80%) and a held-out test cohort (20%) using stratified sampling. Five algorithms were evaluated: logistic regression, support vector machine with radial basis function kernel, random forest, extra trees, and gradient boosting. The final model was selected by mean cross-validated AUROC, refitted on the full training cohort, and evaluated once in the held-out test cohort. Interpretability analyses examined global feature importance and distributional patterns of leading predictors. Results: Gradient boosting was prespecified by cross-validation in the training cohort. The model achieved an AUROC of 0.872 (95% CI: 0.769-0.952) and an AUPRC of 0.883 (95% CI: 0.780-0.959) in a held-out test cohort, with sensitivity of 0.750 and specificity of 0.812. Conclusions: Longitudinal clinical laboratory tests obtained during routine care contained informative and clinically plausible signals for P-TMA risk. Notably, cystatin C at week 6 showed promise as an early monitoring indicator.